HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

Bibliographic Details
Main Authors: Martin, Allison, Moore, Cecilia L., Mallon, Patrick W. G., Hoy, Jennifer F., Emery, Sean, Belloso, Waldo H., Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Format: Online
Language:English
Published: Public Library of Science 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813715/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813715/

Similar Items